Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion

Chest

Volumn 143, Issue 4, 2013, Pages 1146-1150

  Sato, Nahoko ^a   Kojima, Keisuke ^a   Horio, Yuko ^a   Goto, Eisuke ^a   Masunaga, Aiko ^a   Ichiyasu, Hidenori ^a   Kohrogi, Hirotsugu ^a  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOSTEROID; DRUG METABOLITE; KREBS VON DEN LUNGEN 6; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MONODESETHYLAMIODARONE; OXYGEN; POLYMYXIN B; PREDNISOLONE; SURFACTANT PROTEIN D; TORAYMYXIN; UNCLASSIFIED DRUG;

ABNORMAL RESPIRATORY SOUND; ACUTE RESPIRATORY FAILURE; ADULT; ARTERIAL OXYGEN TENSION; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EXERCISE; EXERCISE TOLERANCE; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOPERFUSION; HUMAN; HYPOXEMIA; LIVER TOXICITY; LUNG INFILTRATE; LUNG LAVAGE; LUNG TOXICITY; MACROPHAGE; NEUTROPHIL COUNT; OXYGEN SATURATION; OXYGEN TENSION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULSE OXIMETRY; RESPIRATORY FAILURE; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84875968914     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0994     Document Type: Article

References (12)

1. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol. 1999; 84 (9A) : 37R - 45R.
2. Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J. 2007; 71 (10) : 1610 - 1616.
3. Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 2). Chest. 1988; 93 (6) : 1242 - 1248.
4. Schwaiblmair M, Berghaus T, Haeckel T, et al. Amiodaroneinduced pulmonary toxicity: an under-recognized and severe adverse effect. Clin Res Cardiol. 2010;99(11):693-700.
5. Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 1). Chest. 1988; 93 (5) : 1067 - 1075.
6. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009; 301 (23) : 2445 - 2452.
7. Hara S, Ishimoto H, Sakamoto N, et al. Direct hemoperfusion using immobilized polymyxin B in patients with rapidly progressive interstitial pneumonias: a retrospective study. Respiration. 2011; 81 (2) : 107 - 117.
8. Yokoyama T, Tsushima K, Yamamoto H, et al. Polymyxin B-immobilized fiber column hemoperfusion treatment for drug-induced severe respiratory failure: report of three cases. Intern Med. 2010; 49 (1) : 59 - 64.
9. Horio Y, Ichiyasu H, Masunaga A, et al. Effect of direct hemoperfusion using polymyxin B-immobilized fiber column for patients with rapidly progressive interstitial pneumo nias [Abstract]. Am J Respir Crit Care Med. 2012; 185 : A5820.
10. Quaglino D, Ha HR, Duner E, et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structureactivity relationship. Am J Physiol Lung Cell Mol Physiol. 2004; 287 (2) : L438 - L447.
11. Camus P, Mehendale HM. Pulmonary sequestration of amiodarone and desethylamiodarone. J Pharmacol Exp Ther. 1986; 237 (3) : 867 - 873.
12. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J. 1983; 106 (4 pt 2) : 840 - 847.